Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Will Update Gleevec Label With Potential Heart Failure Risks

This article was originally published in The Pink Sheet Daily

Executive Summary

Company to conduct further studies to elucidate risks shown in preclinical models.

You may also be interested in...



Gleevec Label Updated With Cardiovascular Risk Language

Letter to physicians notes a small chance for CHF and left ventricular dysfunction with imatinib exists, but patients with or at risk for cardiac disease should be closely monitored.

Gleevec Label Updated With Cardiovascular Risk Language

Letter to physicians notes a small chance for CHF and left ventricular dysfunction with imatinib exists, but patients with or at risk for cardiac disease should be closely monitored.

Gleevec Cardiotoxicity Side Effect Reported In Nature Medicine

Other tyrosine kinase inhibitors could also lead to heart problems, the study says. Nonetheless, researcher calls Novartis' Gleevec a "wonderful drug," citing efficacy benefit.

Topics

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel